Naver Presented Total 11 Thesis Papers at the AI Society “NeurIPS 2022” – “Reaffirming AI R&D Capabilities at a Global Level!”
Naver announced that it had published more than 10 papers at “NeurIPS 2022 (Conference on Neural Information Processing Systems)”, one of the world’s most prestigious AI conferences.
NeurIPS is the world’s largest machine learning society, and the competition is so fierce that the paper adoption rate is only about 25%. NeurIPS, which celebrated its 36th anniversary this year, was held offline in New Orleans, USA from November 28th to December 3rd, local time, and will be held online until the 9th.
At NeurIPS, Naver published a total of 11 papers (8 from Naver Clova and 3 from Naver Labs Europe), and was recognized for its AI research achievements at a global level. In addition to the publication at NeurIPS this year, Naver also published more than 10 regular papers at the most prestigious societies in the field of machine learning and computer vision, such as ICLR, CVPR, and ECCV, proving its AI technology at the highest level in Asia.
In particular, while the “multimodal” generation technology that converts text into images is rapidly developing, it drew attention by presenting a generalized index that can effectively evaluate the quality of how much the generated image matches the contents of the input text.
This technology is also highly practical in case of describing a given image with text or evaluating robot motion that executes commands based on text. In addition, the paper analyzed the principles of widely used data augmentation techniques in order to improve the performance of image recognition models, and Naver presented a study proposing more effective augmentation techniques, “Hmix” and “Gmix”.
Joint research results through Seoul National University and KAIST AI Research Center also stood out at the conference. A study on data augmentation techniques for mitigating bias in AI models (Seoul National University) and a research on data generation techniques through compression of learning data (KAIST) were introduced respectively, and the research on speech synthesis through the collaboration with Korea University was also presented. Naver announced the establishment of a research center with Seoul National University and KAIST in May 2021, and has continued the close research cooperation in the field of super-scale and ultra-creative AI.
In addition, Naver participated as a Platinum Sponsor of the conference, prepared a special booth during the conference, and actively engaged in global technology branding and AI talent exchange. With more than 10,000 AI researchers from around the world attending the event, numerous researchers and AI company officials also visited the Naver booth and showed interest. During the conference, Naver organized the ‘NAVER Night’ event to introduce Naver’s latest technology and interact with AI researchers, and also helped the “K-pop in NeurIPS” event, where the participants who were into K-Pop gathered and built their network.
Ha Jung-woo, director of AI Lab at Naver Clova, who also served as the Social Chair of the NeurIPS Organizing Committee, said, “Through continuous investment in advanced research in the AI field and active industry-university cooperation with excellent research institutes at home and abroad, Naver’s AI R&D capabilities are recognized globally.” He added. “Based on differentiated technology, we will work hard to provide more innovative services to the users, while securing AI capabilities that are key to NAVER services and business through our future technology R&D.”
Yura, yuMDL&FabePLM Solution Passes NIPA Quality/Performance Verification
Yura Co., Ltd. announced that its solutions, yuMDL (access-based smartphone security) and FabePLM (product information management), passed the “Cloud Service Quality/Performance Verification” of the National IT Industry Promotion Agency (NIPA) and obtained a certificate.
The cloud service quality and performance verification project, which NIPA is in charge of and is carried out by the Korea Association of Cloud Industry (KACI) and the Telecommunications Technology Association (TTA), is based on quality performance standards notification for improving the quality and performance of cloud service providers and user trust. Establishment and operation of a comprehensive support system is strictly evaluated and verified, and a confirmation is issued.
yuMDL is a service that prevents information leakage within a company through smartphone camera shooting. It can be applied immediately without a separate construction period, and the cost is reasonable, so the satisfaction of the adopting company is high. Depending on the target, the service provides “employee smartphone security” that restricts employees from smartphone photography, and “visitor smartphone security” that restricts visitors from smartphone photography.
In particular, it provides an additional security camera so that there are no problems using the mobile office within the company due to camera shooting restrictions for employees. The security camera can be used for mobile work by taking and sharing photos and videos, scanning barcodes, and providing APIs. yuMDL obtained GS (Good Software) 1st grade certification in 2020 and even obtained a cloud service quality and performance confirmation in 2022 to provide customers with services of excellent quality and performance.
FabePLM develops and applies its own framework (yuFRAME) based on its experience and technology of supporting the manufacturing industry for more than 20 years, so that different processes can be easily and quickly applied to each company. It is possible to provide optimal services by relieving the burden of on-premise process, which requires high cost investment when adopted, and by selecting and adding necessary modules.
Basic services include △project management module that organizes development procedures into WBS △technical data management that enhances work efficiency through quick technical data search △BOM data management and information change management through ERP linkage with design change module.
Yura’s IT business division, an affiliate of an automobile parts manufacturer, has developed its own systems necessary for product and parts development and production, such as electronic CAD, PLM, QMS, MES, big data, and mobile apps, starting with the development of the PDM system in 2003. Developed independently and applied both domestically and internationally, it provides optimized solutions based on the company’s experience and technology. In 2018, it obtained SP (SW Process Quality) Level 2 certification and was recognized for its excellence in project execution capabilities.
Theragen Bio Patented AI-based Cancer Vaccine Design Program
Theragen Bio has completed patent registration for “device for predicting immunogenicity of synthetic long peptides, method for predicting immunogenicity and computer program,” which is from its AI-based cancer vaccine development platform, DEEPOMICS® NEO.
The patent registered this time is the method to effectively measure the immunogenicity of Synthetic Long Peptide (SLP) in neoantigen vaccines and designs a vaccine that can maximize the immunogenicity of neoantigen candidates selected through genome analysis and experiments.
DEEPOMICS® NEO quantifies the immunogenicity of the SLP presented by the injection in the body of the patient’s target cells and find ▲HLA binding ability of the neoantigen ▲T cell recognition level ▲cleavage prediction information ▲peptide sequence information, etc. It is a program that finds the optimal location of a mutation in the SLP sequence with quantification of the data. The company expects it to be a groundbreaking technology essential for the development of personalized neoantigen vaccines in the future.
Neoantigen candidate screening programs developed so far only provided the function of predicting the neoantigen that induces the patient’s immune response among the mutations found by genome analysis, and there has been no program that predicts the position of the mutation that maximizes the immunogenicity of the vaccine. However, therapeutic cancer vaccines contain neoantigen candidate mutations in the form of long peptide sequences, and the immune response varies greatly depending on the location of the mutation in the SLP sequence, so the need for a program that predicts the location of the mutation has been continuously emerging.
In addition, in order to activate an immune response to mutations of cancer cells, T cells must be stimulated by antigen presenting cells (APCs) and dendritic cells, not cancer cells. The development of an algorithm that predicts the binding between neoantigens and major histocompatibility complex (MHC), MHC class I (MHC I), and class Ⅱ (MHC Ⅱ) has led to various clinical applications of personalized neoantigen cancer vaccines. It plays an important role in expanding and applying the clinical result to various types of carcinoma.
“The development of a vaccine design algorithm that maximizes neoantigen immunogenicity will be an important focus of future neoantigen vaccine research. The cancer vaccine designed with this patent showed superior immune response induction and treatment effects in preclinical models compared to competitors, and is an advanced technology that can be applied to all vaccine designs.” said Baek Soon-myeong, CTO of Theragen Bio. He added, “We will achieve the goal of developing a cure for incurable cancer and a customized medicine through steady research.”
Theragen Bio is researching and developing a therapeutic neoantigen cancer vaccine that helps activate immune cells by selectively stimulating T cells that recognize tumor mutations. In the field of neoantigen cancer vaccine, personalized treatment is possible in that the neoantigens can be selected based on mutation information of different tumors for each individual, so it is drawing attention in the development of cancer treatments.
Meanwhile, the company has completed registration of patents for a total of 6 cancer vaccine platforms, including ▲2 patents for DEEPOMICS® MARKER and ▲4 patents for DEEPOMICS® NEO. In the future, the company plans to continue R&D on personalized treatment targets and new drug development for each patient to develop genome-based innovative solutions with DEEPOMICS®, a genome big data platform.
CHA Vaccine Institute, Domestic Clinical Phase 1 for Its “Shingles Vaccine” Approved!
CHA Vaccine Research Institute, a subsidiary of CHA Biotech, has received approval from the Ministry of Food and Drug Safety for a phase 1 clinical trial plan (IND) for ‘CVI-VZV-001’, a candidate for recombinant protein zoster vaccine.
CHA Vaccine Research Institute plans to evaluate the safety and tolerability of CVI-VZV-001 by dose in 24 healthy adults between the ages of 50 and 65 in this clinical trial. Then it is planning to observe the maximum administered dose, the recommended dose for phase 2 clinical trials, and immunogenicity.
CVI-VZV-001 is a recombinant protein shingles vaccine based on the immune enhancement platform ‘Lipo-pam™’ developed by CHA Vaccine Research Institute. Lipo-Pharm prevents shingles by inducing a cellular immune response and suppressing the activation of the zoster virus in a latent infection state.
Shingles occurs when the varicella-zoster virus lies dormant in the nerve cells and weakens the immune system. Currently, two types of prophylactic vaccines have been commercialized: live attenuated vaccines and recombinant protein vaccines. Among them, live attenuated vaccines are evaluated as lacking in the protective effect for the elderly, while currently released recombinant protein vaccines have excellent protective effects even in the elderly, but the immunostimulant included in the vaccine causes severe pain.
The immune enhancing substance applied to CVI-VZV-001 is also used in a chronic hepatitis B treatment vaccine currently in phase 2b in Korea, but there are no reports of severe pain. The recombinant protein vaccine of the CHA Vaccine Research Institute is expected to suppress “post-herpetic neuralgia (PHN)” by maximizing the cellular immune response in the body.
“CVI-VZV-001 is expected to have a more preventive effect by improving the problems of existing vaccines and applying the immunity enhancement platform technology independently developed by the CHA Vaccine Research Institute,” said Yeom Jung-sun, CEO of the CHA Vaccine Research Institute. “Starting with this phase 1 clinical trial, we will do our best to accelerate the commercialization of the product by promptly conducting clinical trials.”
Quick News
Krafton, Survival Horror Game ‘The Callisto Protocol’ Global Release
Krafton Inc.’s independent studio Striking Distance Studios Inc., (hereafter referred to as SDS) globally released the survival horror game ‘The Callisto Protocol’. The Callisto Protocol is game that tells the survival story that happens due to an unidentified epidemic that spreads on ‘Callisto’, Jupiter’s Satellite, in 2320. It can be played on consoles such as Play Station® 4 and 5, Xbox One, Xbox Series X·S etc., and on PCs through Steam and the Epic Games Store.
Unlike other horror games, in order to bring out the feeling of ‘desperate struggle for survival’, Callisto Protocol is characterized by an appropriate mix of close and long-distance combat. It has implemented a combat system that requires strategic combat using various weapons such as guns, stun clubs, grip (a weapon that uses gravity), etc., to fight against strange creatures.
Kakao, Announces Measures to Prevent the Recurrence of Service Failures at the Developer Conference!
Kakao analyzed the service failure due to the fire at the Pangyo SK C&C Data Center on October 15th and revealed its measures to prevent the recurrence of service failures at 11 a.m. on the 7th at the developer conference ‘If Kakao dev 2022 (hereafter referred to as If Kakao)’.
During the ‘Our Social Mission’ keynote, co-chairman Hoon Namgoong of the Prevention of Recurrence Committee stated Kakao’s social calling and determination to prevent similar accidents. The top priority Kakao ESG projects will be set to ‘provide services stably’, and in order to improve the infrastructure, practical tasks will be set up from largely three perspectives of analyzing past causes, present recurrence prevention measures, and future investment.
Furthermore, he announced that they will significantly strengthen the infrastructure organization and create a stable service environment with co-chairman Woo-Chan Ko of the Prevention of Recurrence Committee in the lead.
Robot Café B;eat, Bringing in the Christmas Season with the ‘Rudolf Update’ 17 Expressions Updated!
The robot café B;eat put on unique cute, and lively expressions that stir the ‘human touch’ sentiments on the displays that are the equivalents of the faces on the robot baristas, and is receiving positive responses from consumers. B;eat brought in the Christmas Season by adding a red nose to the 17 main expressions, some of which are ▲Wink ▲Smile ▲Hard-Working Mode ▲Tears ▲Shooting Hearts ▲Twinkling Eyes ▲Mischievous Eyes ▲Look Around, etc., updating them to the ‘Rudolf Version’.
Robot café B;eat where robot baristas work 24 hours a day, is a future-oriented café that is an ideal solution for small capital start-ups, as the entire process from ordering to payment, manufacturing, and pickup is performed unmanned, with no need for resident manpower.
Source: Pangyo Techno Valley Official Newsroom
